Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).

Geoffrey A BlockAnthony J BleyerArnold L SilvaDaniel E WeinerRobert I LynnYang YangDavid P RosenbaumGlenn M Chertow

Published in: Kidney360 (2021)

Tenapanor reduced serum phosphate concentrations and maintained control of serum phosphate in participants receiving maintenance dialysis, with an acceptable safety and tolerability profile.